AstraZeneca wagers $200M on Ionis’ next chance at a rare disease drug
AstraZeneca is betting that Ionis' second drug for transthyretin amyloidosis, or ATTR, will stand out where its first one couldn't.
Ionis developed Tegsedi for years...
Continue Reading →
